



RESEARCH ARTICLE

Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection

Robert J. Greenstein;

Consultant Department of
Surgery, James J. Peters.
Veterans Affairs Medical Center,
Bronx NY 10468. USA.



OPEN ACCESS

PUBLISHED

31 July 2024

CITATION

Greenstein, R., J., 2024. Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection. Medical Research Archives, [online] 12(7). <https://doi.org/10.18103/mra.v12i7.5541>

COPYRIGHT

© 2024 European Society of Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI

<https://doi.org/10.18103/mra.v12i7.5541>

ISSN

2375-1924

ABSTRACT

For more than a century, there has been controversy whether Crohn's disease is a cryptic zoonotic mycobacterial infection. In this manuscript we address two, usually ignored, critical elements that suggest that this concern is probably correct. First: human genetic defects identified in Crohn's disease are associated with increased susceptibility to mycobacterial infections. Second: multiple pharmaceutical agents that are used in Crohn's disease are misnamed. Many "anti-inflammatories" and "immune modulator" medications have dose dependent inhibition of mycobacteria in culture. Accordingly, their primary mechanism of action are as antimycobacterial antibiotics. Failure to incorporate these data renders all previous antibiotic studies in Crohn's disease irrevocably flawed. Finally, incorporating these genetic and antibiotic data, we suggest the necessary clinical studies to address the hypothesis that Crohn's disease is a zoonotic infection.

Introduction

The thesis that Crohn disease (CD) is due to a mycobacterial infection had been posited for more than a century¹. The concept remains controversial and is conventionally met with denial^{2,3}, although a reanalysis of those data has been advocated⁴. It is important to consider that, to this day, Koch's postulates⁵ have not been met for *M. Leprae* and leprosy. (*M. Leprae*, an obligate intracellular parasite, has never been grown in culture⁶, consequent to massive gene decay⁷. Accordingly Koch's second and fourth postulates cannot be satisfied.) In contrast, in 2003 I posited that Koch's postulates had already been met for *M. avium* subspecies *paratuberculosis* (MAP) and Crohn disease, albeit in separate experiments⁸.

This 22-minute video encapsulates my overall opinion about the Crohn's zoonotic conundrum. (<https://vimeo.com/413736108/59ec7b1545>)

The overarching opinion of those who contend that CD is infectious, is that it is a human form of Johne disease (JD), a mycobacterial disease, caused by MAP, that is found in multiple vertebrates⁹. Johne disease is a ravage on the agricultural community¹⁰. Those concerned that CD is infectious contend that MAP is zoonotic¹¹ and that it is transmitted to humans in the food chain and potable chlorinated municipal water¹².

Map was first cultured from a human with CD in 1984¹³. MAP RNA (indicating viability) was first identified in the intestinal tissue of both CD and ulcerative colitis in 1966.¹² This latter observation led to the hypothesis that all of inflammatory bowel disease was a spectrum of diseases caused by MAP¹⁴.

Generally, the scientific community requires independent reproducible proof to accept a premise. In infectious diseases it is more than just documenting the presence of an organism. The suggestion that gastric "peptic" ulceration was consequent to a *H. pylori* infection^{15,16} was initially met with almost universal derision and condemnation. It was only when "peptic" ulcers were cured with the eradication of *H. pylori* that the

epiphenomenon (present but irrelevant) contention was discredited. 25 years later Warren and Marshall received their Nobel prizes for proving an infectious etiology for "peptic" ulcer disease.

If CD is indeed due to MAP, why is it not cured, or at least significantly ameliorated, by appropriate antiMAP therapies? The purpose of this manuscript is to address two aspects that are critical to understanding why all previous antibiotic studies of the CD/MAP conundrum are irretrievably flawed¹⁷. Finally, it will indicate what clinical studies are necessary to satisfactorily test the CD/MAP hypothesis.

First, it will focus on genetic defects that have been identified in inflammatory bowel disease (IBD.) Their function of the wild type genes will be addressed and why the presence of mutations indicate susceptibility to mycobacterial infections. Second, it will present an overview of unacknowledged and misnamed pharmacological agent that are commonly used in the therapy of IBD. Their primary function is as antiMAP antibiotics.

Genetics:

A detailed analysis of more than 200 loci associated with IBD (see¹⁸⁻²⁰ for reviews) is beyond the scope of this manuscript. In brief, IBD genetic analyses present a consistent, yet predominantly ignored, narrative on the potential susceptibility to mycobacterial infection as being associated with and possibly causative of IBD. Defects in these loci impair the host immune response to infectious organisms, particularly mycobacteria.

NOD2 was the first genetic defect identified in Crohn disease^{21,22}. In 2005 Hugot, one of the initial NOD2 investigators²¹, considered the NOD2 finding to be irrelevant in causation or therapeutic responses and was not worthy being identified in CD patients. (Opinion voiced at Inflammatory Bowel Disease Conference: Munster; Germany. Sept 2-3, 2005.)

Comparisons with acknowledged mycobacterial diseases, particularly tuberculosis, leprosy²³ and

Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection

Johne disease, provide critical insights into understanding IBD⁸. Wild-type NOD2 is associated with physiological responses to tuberculosis resulting in the production of protective pro-inflammatory cytokines, mediated in part through NF-kappa B pathways²⁴⁻²⁶. In contrast, human NOD2 defects are associated with susceptibility to tuberculosis²⁷. With *M. leprae*, a NOD2 defect is associated with lepromatous (the more aggressive form of) leprosy^{28,29}. An editorial accompanied the leprosy/NOD2 manuscript. It concluded "these common genetic signatures support, albeit indirectly, the proposal that a proportion of Crohn's disease cases may have a mycobacterial cause"³⁰. It is also of considerable interest that NOD2 defects are associated with increased susceptibility³¹ to Johne disease⁹ (a bovine MAP infection evocative of Dalziel/Crohn disease^{1,32})

Subsequently a study of 75,000 human genomes provided an unsurpassed insight³³ Half of the subjects had IBD, and half were healthy controls. The study was from 71 preeminent world-wide institutions, had 106 authors, 347 collaborators and the analyses were conducted at the Sanger Institution at the University of Cambridge UK. The manuscript concluded: "We also observe considerable overlap between susceptibility loci for IBD and mycobacterial infection"³³.

Yet another example of how an IBD genetic defects impairs responses to mycobacterial infections is LY75¹⁸. This encodes CD205 (aka DEC-205), which is highly expressed on gut dendritic cells (immobile macrophages which endocytose mycobacteria.) Wild-type CD205 regulates endocytosis, T-cell function and homeostasis³⁴, and protects against pulmonary Tb^{35,36}.

Genome wide association studies (GWAS) show common susceptibility loci in leprosy²³ and IBD. Of eight susceptibility loci identified in leprosy (NOD2²⁸, TNSNF15³⁷, LRRK2³⁸, IL23R & LCC1/CCDC122³⁸) five are associated with IBD. Furthermore, by comparing known IBD susceptibility loci with leprosy, two more leprosy loci, IL18RAP/IL18R1 AND IL12B were identified³⁹.

The authors accept prevailing dogma that "our study has further demonstrated the shared genetic susceptibility basis between inflammation and infectious diseases"³⁹. We disagree with their conclusion. We consider that that both IBD and leprosy are mycobacterial infectious disease.


The question is: Why has an infectious etiology of UC and CD been missed?

Unacknowledged Pharmacological Effects.

There are two mainstream forms of therapies in IBD. The initial forms were either called "anti-inflammatories", because, when used, inflammation diminished, or "immune modulators", because pro-inflammatory cytokines diminished. These include 5ASA⁴⁰, methotrexate, 6MP and azathioprine. More recently there has been the introduction of multiple "biologics."

The central thesis of this manuscript is that the mechanism of action of "anti-inflammatories" and "immune modulators" has long been misinterpreted. We suggest that nomenclature simply describes a secondary physiological response. Their primary mechanism of action is, in my opinion, as antiMAP antibiotics.

Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection



Legend to Figure 1: Shown on the left is prevailing therapeutic dogma for IBD. Shown on the right is our contention that the prevailing dogma is wrong. The green triangle identifies antiMAP antibiotics. The brown triangle identifies agents that are actual anti-inflammatories. These include steroids and a variety of cytokine inhibitors (conventionally referred to as "Biologics.")

In 1940 salicylic acid was shown to increase the growth of the tuberculosis bacillus⁴¹. This led to manipulation of the salicylic molecule to see

whether it could decrease the rate of growth of mycobacteria in general. This was done by adding an amino group to the carbon ring of salicylic acid.

The Effect of Salicylate on the Oxygen Uptake of the Tubercle Bacillus

Bernheim, F.
Science 1940, 92, 204

Salicylic acid




FIG. 1. The oxygen uptake of 0.5 cc of the suspension of tubercle bacilli alone and with salicylate and benzoate at pH 6.7 and 37° C.

Legend to Figure 2: Shown is the increase in O₂ consumption when M. tb was supplemented by salicylic acid.

In 1942 Sulfanilamide was introduced in the therapy of rheumatoid arthritis as well as ulcerative colitis⁴². It was a combination of 5-ASA and sulphapyridine. In the therapy of IBD, sulphapyridine is no longer used. This due to the empirical observation of lack of clinical efficacy of the sulphapyridine moiety⁴³⁻⁴⁵. In contrast, 5ASA

alone is now considered to be a "first line" therapy for several inflammatory diseases including ulcerative colitis and some forms of CD⁴⁶. One formulation, Olsalazine, is simply two molecules of 5ASA.

The precise mechanism of action of 5-ASA remains unknown⁴⁷. Amongst speculations are: "the


Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection

hypothesis is that it modulates the inflammatory response derived from the cyclooxygenase and lipoxygenase pathways, decreasing the synthesis of prostaglandins and leukotrienes⁴⁷, suppression of IL-1⁴⁸, blocking TNF-alpha suppression and NF kappaB activation⁴⁹ and decreased transcriptional activity due to Interleukin-1-stimulated NF-kB RelA/p65 Phosphorylation⁵⁰. None of these postulated mechanisms are accepted⁴⁷

We herein posit a data based, published⁵¹, never refuted, hypothesis as to the primary mechanism of 5ASA in IBD. It is that 5-ASA is a bacteriostatic

antiMAP antibiotic. The fact that it is an antibiotic should not be surprising. 5-ASA was introduced in 1942⁴². Its author, Nanna Svartz, Chairperson of Medicine at the Karolinska Institute in Stockholm, hypothesized that its mechanism of action was as an antibiotic (for review see⁴⁶) The structural difference between 5-ASA and the universally acknowledged antibiotic PAS (para-amino salicylic acid) is merely that the amino group, on the salicylic six carbon ring, is one carbon atom displaced.

Salicylic Acid & Derivatives



Svartz N. 1942
*Acta Medica Scand*110:577-598
“Anti-Inflammatory”

Lehmann J. 1946
The Lancet (I) 14-16
Antibiotic

Legend to Figure 2: The structural similarity between 5-ASA and PAS is immediately apparent. PAS could be called 4-ASA. 5-ASA could be called Meta Amino Salicylic Acid.

It is appropriate to inquire why it took 62 years from the introduction of 5-ASA in 1942⁴² until our manuscript in 2005⁵¹, to document dose dependent inhibition in culture of any mycobacterium, particularly MAP. It took an additional 13 years (2018) until 5-ASA dose dependent inhibition of *E. Coli* in culture was reported⁵². The explanations of this prolonged interval from introduction to documentation of antibiotic activity are technical.

They have previously been addressed in detail⁵³. In brief, reliable culture of MAP first had to be established. Initial isolation requires Herrold’s egg yolk slopes and mycobactin J. The latter is obligatory, as MAP is unable to constitutively chelate iron. Using agar slopes, inhibition can only be detected with potent bactericidal antibiotics. Bacteriostatic dose dependent inhibition (such as we demonstrate with 5-ASA⁵¹) requires culture in liquid as well as an exquisitely sensitive detection

Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection

mechanism⁵⁴ Our published data were generated in ¹⁴CO₂ radiometric Bactec 460® (Becton Dickenson NJ.) Because of onerous radionucleotide regulation compliance¹⁴, disposal difficulties and the fact it was only semi-automatic, the Bactec 460 is no longer produced or supported. It has been replaced with the automated, fluorometric MGIT® Bactec 960® (Becton Dickenson NJ.) The MGIT system is less sensitive than the Bactec 460, particularly for non-tuberculous mycobacteria⁵⁵⁻⁵⁷. In contrast to our 5-ASA dose dependent inhibition data generated using Bactec 460⁵¹, using MGIT we were not able to demonstrate MAP inhibition by 5-ASA (unpublished observations.)

In addition to 5-ASA, there are other medications that are routinely used in the therapy of IBD. Using Bactec 460 we show dose dependent MAP inhibition in many. We document antiMAP antibiotic activity of methotrexate⁵⁸, 6-MP⁵⁸, Cyclosporine A⁵⁹, Rapamycin⁵⁹, Tacrolimus⁵⁹, the thioureas methimazole⁶⁰ and thiourea⁶⁰ (used in the treatment of thyrotoxicosis) and the 1-hydroxypiperidine- 2,6-dione (but not the phthalimide) moiety of thalidomide⁶¹

Others show, using fluorometric MGIT culture, that 6-MP and azithromycin inhibit MAP in culture^{62,63}. A non-culture study identified MAP DNA in IBD patients and controls⁶⁴ In two IBD cohorts MAP DNA was not found. These were IBD patients treated with methotrexate or 6-MP⁶⁴. A possible rational, data based, explanation of this lack of MAP DNA in IBD is that the action of methotrexate and 6-MP is bactericidal, and that MAP had been eradicated, or diminished to undetectable levels.

Role of Vitamins A & D in inhibiting mycobacterial growth.

The utility of Vitamin A in combating infection was first published in 1929⁶⁵. Subsequently the clinical use of Vitamin A in treating infectious diseases was extensively studied until the 1940's (see a 1999 comprehensive and informative review⁶⁶). With the

introduction of sulfa and subsequently penicillin antibiotics in the mid 1930's, investigation of the use of Vitamin A floundered. The precise mechanism of how Vitamin A acted in treating infectious disease was never conclusively defined or accepted but is generally thought to improve the immune system of the infected eukaryotic host. In antiquity, the value of sunlight in the treatment of tuberculosis was recognized by Hippocrates, as well as by the Incas for multiple diseases (see⁶⁷ for review.) In 1903 Rollins began treating tuberculosis in Switzerland with "heliotherapy"⁶⁸. It was assumed that elevation in vitamin D was the mechanism of efficacy. The precise role of Vitamin D as an anti-infective remains controversial⁶⁹. Adequate doses or supplementation improves clinical outcomes in active tuberculosis⁷⁰. Well studied is the host immune system, particularly the monocyte/macrophage response⁷¹. High dose vitamin D supplementation in Crohn's disease improves outcomes⁷², but interestingly not in those with the NOD2 defect⁷³. As with Vitamin A, benefits of supplementation are assumed to be predominantly on improving the immune response of a mycobacterial infected host.

We hypothesized that both Vitamins A and D could directly inhibit growth of prokaryotes, particularly mycobacteria. The effect of four fat soluble vitamins (A, D, E & K) on growth of three species of mycobacteria (*M. Tb*, *M. avium* subspecies *avium*, and MAP) was evaluated. Vitamins E, K and the Vitamin A precursor b-Carotene were not inhibitory. Vitamin A, its metabolites Retinyl acetate, Retinoic acid, 13-cis Retinoic acid and Vitamin D inhibited all mycobacterial growth in all species studied⁷⁴.

We show that, in radiometric culture, Vitamins A, some of its metabolites and Vitamin D, inhibit several species of mycobacteria in a dose dependent manner. These data indicate that Vitamins A & D⁷⁵, at no risk, can be used as supplements and adequate levels should be maintained in a multitude of possible mycobacterial diseases.

Role of a veterinary “growth enhancer” in inhibiting mycobacterial growth.

Introduced in 1967, Monensin is a carboxyl polyether ionophore⁷⁶. In the poultry industry it has been employed as a coccidiostat since 1971 (see⁷⁷ for review.) In the cattle industry it is extensively used as a “growth enhancer” because it decreases food intake, increases weight, prolongs lactation⁷⁸, and “lipogenic:gluco- genic volatile fatty acids and NH₃-N concentration were lower, and apparent digestibility of dry matter, organic matter, crude protein, and gross energy were higher with “ Monensin⁷⁹. Worldwide the veterinary cattle industry is ravaged by MAP¹⁰. Forty two years after Monensin’s introduction, we show a heretofore previously undocumented dose dependent inhibition of MAP in culture⁸⁰. Accordingly, we posit that the beneficial effect of Monensin in cattle may be due, at least in part, to antiMAP antibiotic activity.

We consider all prior antibiotic studies in CD are irrevocably flawed^{17,81}. A pivotal antibiotic study in CD was considered negative^{2,3}, although others suggest it was positive⁴. In that study, at the discretion of the referring physician, patients were permitted “immunomodulator therapy with azathioprine/6-mercaptopurine (6/MP) at a stable dose for at least 6 months prior to enrolment; and 5-aminosalicylates at a stable dose for at least 4 weeks prior to entry”³. The accompanying editorial commented “Interestingly, in Selby *et al*’s trial, concomitant use of immunomodulatory therapy was the only parameter that was associated with a significantly greater response in the antibiotic group”². The editorial then cited our manuscript⁵⁸, as a possible explanation: “These data are compatible with the hypothesis that clinical improvement in patients with inflammatory bowel disease treated with immuno- modulators could be due to treatment of a MAP infection”.

Two additional vignettes. We consider that the word “placebo” is inappropriate in antibiotic studies where the use of “anti-inflammatories” or “immunomodulators” is permitted in an

uncontrolled and *ad libitum* manner. A more scientific, accurate and appropriate term is “Add On”⁸¹. Additionally, there is a simple rule-of-thumb to differentiate antiMAP antibiotic action from genuine anti-inflammatory action⁸¹. It is time to clinical response. As with leprosy and tuberculosis, antibiotic therapy requires weeks, months or years. In contrast, a genuine anti-inflammatory action is virtually immediate. Following an infusion, a patient feels clinical improvement immediately, colloquially referred to as “the parking lot effect.”

What studies need to be performed?

Considering the forgoing, it is logical to ask how to refute or confirm that MAP is zoonotic. Appropriate clinical studies need to be re-analyzed³ or performed in IBD in general¹⁴ and in CD in particular¹¹. The design must consider the unacknowledged antiMAP antibiotics that have been identified in this article as well as accepted antiMAP antibiotics³. More desirably naive IBD/Crohn patients could be divided into two groups. One, the “Add On”⁸¹ group, will include any of the pharmaceuticals with antiMAP activity identified in this article as well as acknowledged antiMAP antibiotics³. The second will permit none of the agents used in group one, and have only true anti-inflammatories (such as steroids) and the biologics. Finally, because of the tardiness of the replication rate of MAP, as with prior studies³ a minimum of two years will be required to get meaningful analyses.

MAP is ubiquitous in the environment, food and water. Accordingly, all treated individuals will be re-exposed to viable MAP. Predisposing genetic defects must be identified. This is because following cessation of antiMAP therapies, a recurrence of disease may occur. This may simply indicate re-exposure to MAP in a genetically compromised individual and indicate the need for lifelong therapy, rather than failure of the study.

Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection

Conflict of Interest:

None.

Funding:

None.

Acknowledgements:

None.

Financial disclosure:

Intramural funds for data published from my laboratory were from the Bronx Veterans Medical Research Foundation, Inc. a charity at the James J. Peters VAMC Bronx NY. The fund had no role in study design, data collection and analysis, decision to publish, or preparation of those manuscripts. There was no extramural funding for those studies.

Competing Interest statement:

RJG has submitted patents based on the hypotheses tested in prior publications.

Patents Issued

US Patent # 7,846,420: Issue Date Dec 7, 2010. *Mycobacterium Avium* Subspecies *Paratuberculosis* Vaccines and Methods for Using the Same. (Now lapsed)

US Patent # 7,902,350: Issue Date March 8, 2011. Method for Monitoring the Efficacy of a *Mycobacterium Avium* Subspecies *Paratuberculosis* Therapy. (Now lapsed)

References:

1. Dalziel TK. Chronic intestinal enteritis. *British Medical Journal* 1913;ii:1068-1070.
2. Peyrin-Biroulet L, Neut C, Colombel JF. Antimycobacterial therapy in Crohn's disease: game over? *Gastroenterology* 2007;132(7):2594-8. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17570230).
3. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. *Gastroenterology* 2007;132(7):2313-9. DOI: 10.1053/j.gastro.2007.03.031.
4. Behr MA, Hanley J. Antimycobacterial therapy for Crohn's disease: a reanalysis. *The Lancet infectious diseases* 2008;8(6):344. (Letter) (In eng). DOI: 10.1016/S1473-3099(08)70104-X.
5. Koch R. Die Aetiologie der Tuberculose. *Berliner Klinische Wochenschrift* 1882;19:221-230.
6. Stewart-Tull DES. *Mycobacterium leprae* - The bacteriologist's enigma. In: Ratledge C, Stanford J, eds. *The Biology of the Mycobacteria, Volume 1: Physiology, Identification, and Classification*. 1 ed. New York: Academic Press; 1982:273-307.
7. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. *Nature* 2001;409(6823):1007-11. (Research Support, Non-U.S. Gov't) (In eng). DOI: 10.1038/35059006.
8. Greenstein RJ. Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. *The Lancet infectious diseases* 2003;3(8):507-14. (<http://www.ncbi.nlm.nih.gov/pubmed/12901893>).
9. Johne HA, Frothingham L. Ein eigenthümlicher fall von tuberculose beim rind (A particular case of tuberculosis in a cow). *Dtsch Zeitschr Tiermed, Vergl Pathol* 1895;21:438-454.
10. Whittington R, Donat K, Weber MF, et al. Control of paratuberculosis: who, why and how. A review of 48 countries. *BMC veterinary research* 2019;15(1):198. DOI: 10.1186/s12917-019-1943-4.
11. Greenstein RJ, Collins MT. Emerging pathogens: is *Mycobacterium avium* subspecies paratuberculosis zoonotic? *Lancet* 2004;364(9432):396-7. DOI: 10.1016/S0140-6736(04)16781-0.
12. Mishina D, Katsel P, Brown ST, Gilberts EC, Greenstein RJ. On the etiology of Crohn disease. *Proceedings of the National Academy of Sciences of the United States of America* 1996;93(18):9816-20. DOI: 10.1073/pnas.93.18.9816.
13. Chiodini RJ, Van Kruiningen HJ, Merkal RS, Thayer Jr. WR, Coutu JA. Characteristics of an unclassified *Mycobacterium* species isolated from patients with Crohn's disease. *J Clin Microbiol* 1984;20(5):966-971.
14. Greenstein RJ, Brown S. A Data-Based Hypothesis That Inflammatory Bowel Disease Unclassified (IBD-U) May Indicate That IBD Is a Spectrum of a Single Infectious Intestinal Disease. *Inflammatory bowel diseases* 2018. DOI: 10.1093/ibd/izy301.
15. Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1983;1:1273.
16. Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1983;1:1273-1275.
17. Greenstein RJ, Cameron DW, Brown ST. Yet Another Flawed "Placebo Controlled" Study in Crohn's Disease? *Foodborne Pathog Dis* 2015;12(9):812. DOI: 10.1089/fpd.2015.1999.
18. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet* 2015. DOI: 10.1038/ng.3359.
19. Cleyneen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. *Lancet* 2016;387(10014):156-67. DOI: 10.1016/S0140-6736(15)00465-1.
20. Ouahed J, Spencer E, Kotlarz D, et al. Very Early Onset Inflammatory Bowel Disease: A Clinical

Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection

Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflammatory bowel diseases 2019. DOI: 10.1093/ibd/izz259.

21. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411(6837):599-603. DOI: 10.1038/35079107.

22. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with a susceptibility to Crohn's disease. Nature 2001;411(6837):603-606.

(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11385577).

23. Sauer ME, Salomao H, Ramos GB, et al. Genetics of leprosy: Expected and unexpected developments and perspectives. Clinics in dermatology 2015;33(1):99-107. DOI: 10.1016/j.clindermatol.2014.10.001.

24. Ferwerda G, Girardin SE, Kullberg BJ, et al. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog 2005;1(3):279-85.

(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16322770).

25. Divangahi M, Mostowy S, Coulombe F, et al. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol 2008;181(10):7157-65. (Research Support, Non-U.S. Gov't) (In eng)

(<http://www.ncbi.nlm.nih.gov/pubmed/18981137>).

26. Behr MA, Semret M, Poon A, Schurr E. Crohn's disease, mycobacteria, and NOD2. The Lancet infectious diseases 2004;4(3):136-7.

(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14998497).

27. Austin CM, Ma X, Graviss EA. Common nonsynonymous polymorphisms in the NOD2 gene are associated with resistance or

susceptibility to tuberculosis disease in African Americans. J Infect Dis 2008;197(12):1713-6. DOI: 10.1086/588384.

28. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med 2009;361(27):2609-18. DOI: 10.1056/NEJMoa0903753.

29. Greenstein RJ, Brown ST. Genomewide association study of leprosy. N Engl J Med 2010;362(15):1447; author reply 1447-8. (<http://www.ncbi.nlm.nih.gov/pubmed/20397291>).

30. Schurr E, Gros P. A common genetic fingerprint in leprosy and Crohn's disease? N Engl J Med 2009;361(27):2666-8.

(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20018963).

31. Pinedo PJ, Buergelt CD, Donovan GA, et al. Association between CARD15/NOD2 gene polymorphisms and paratuberculosis infection in cattle. Vet Microbiol 2009;134(3-4):346-52. DOI: 10.1016/j.vetmic.2008.09.052.

32. Crohn BB, Ginzberg L, Oppenheimer GD. Regional Ileitis. J Amer Med Assoc 1932;99:1323-1328.

33. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491(7422):119-24. (Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't) (In eng). DOI: 10.1038/nature11582.

34. Fukaya T, Murakami R, Takagi H, et al. Conditional ablation of CD205+ conventional dendritic cells impacts the regulation of T-cell immunity and homeostasis in vivo. Proceedings of the National Academy of Sciences of the United States of America 2012;109(28):11288-93. DOI: 10.1073/pnas.1202208109.

35. Dong H, Stanek O, Salvador FR, et al. Induction of protective immunity against Mycobacterium tuberculosis by delivery of ESX antigens into airway dendritic cells. Mucosal Immunol 2013;6(3):522-34. DOI: 10.1038/mi.2012.92.

36. Welsh KJ, Risin SA, Actor JK, Hunter RL. Immunopathology of postprimary tuberculosis: increased T-regulatory cells and DEC-205-positive foamy macrophages in cavitory lesions. *Clinical & developmental immunology* 2011;2011:307631. DOI: 10.1155/2011/307631.
37. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet* 2008;40(8):955-62. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18587394).
38. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet* 2011;43(3):246-52. (Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't) (In eng). DOI: 10.1038/ng.764.
39. Zhang F, Liu H, Chen S, et al. Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy. *Nat Genet* 2011;43(12):1247-51. DOI: 10.1038/ng.973.
40. Noureldin M, Cohen-Mekelburg S, Mahmood A, et al. Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease. *Inflammatory bowel diseases* 2020. DOI: 10.1093/ibd/izaa127.
41. Bernheim F. The Effect of Salicylate on the Oxygen Uptake of the Tubercle Bacillus. *Science* 1940;92(2383):204. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17842973).
42. Svartz N. Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthrits. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations. *Acta Medica Scandinavica* 1942;110:577-598.
43. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. *Lancet* 1977;2(8044):892-5. DOI: 10.1016/s0140-6736(77)90831-5.
44. Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. *N Engl J Med* 1980;303(26):1499-502. DOI: 10.1056/NEJM198012253032602.
45. Campieri M, Lanfranchi GA, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. *Lancet* 1981;2(8241):270-1. DOI: 10.1016/s0140-6736(81)90523-7.
46. Pouchard NA, Greenfield SM, Thompson RP. Mechanism of action of 5-aminosalicylic acid. Mediators of inflammation 1992;1(3):151-65. DOI: 10.1155/S0962935192000243.
47. Nakashima J, Patel P, Preuss CV. Mesalamine (USAN). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.; 2024.
48. Rachmilewitz D, Karmeli F, Schwartz LW, Simon PL. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. *Gut* 1992;33(7):929-32. DOI: 10.1136/gut.33.7.929.
49. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. *Gastroenterology* 1999;116(3):602-9. DOI: 10.1016/s0016-5085(99)70182-4.
50. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. *J Biol Chem* 1999;274(37):26448-53. DOI: 10.1074/jbc.274.37.26448.
51. Greenstein RJ, Su L, Shahidi A, Brown ST. On the action of 5-amino-salicylic acid and sulfapyridine on *M. avium* including subspecies paratuberculosis. *PLoS One* 2007;2(6):e516. DOI: 10.1371/journal.pone.0000516.
52. Zhang S, Fu J, Dogan B, Scherl EJ, Simpson KW. 5-Aminosalicylic acid downregulates the growth and virulence of *Escherichia coli* associated with IBD and colorectal cancer, and upregulates

Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection

host anti-inflammatory activity. *J Antibiot (Tokyo)* 2018. DOI: 10.1038/s41429-018-0081-8.

53. Greenstein RJ, Gillis TP, Scollard DS, Brown ST. *Mycobacteria: Leprosy, a Battle Turned; Tuberculosis, a Battle Raging; Paratuberculosis, a Battle Ignored*. In: Fratamico P, Smith J, Brogden K, eds. *Sequelae and Long-Term Consequences of Infectious Diseases*. First ed. Washington DC 20036-2904: ASM Press. American Society for Microbiology; 2009:135-168.

54. Whittington RJ, Marsh I, McAllister S, Turner MJ, Marshall DJ, Fraser CA. Evaluation of modified BACTEC 12B radiometric medium and solid media for culture of *Mycobacterium avium* subsp. *paratuberculosis* from sheep. *J Clin Microbiol* 1999;37(4):1077-83.

(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10074529).

55. Piersimoni C, Nista D, Bornigia S, Gherardi G. Unreliable detection of *Mycobacterium xenopi* by the nonradiometric Bactec MGIT 960 culture system. *J Clin Microbiol* 2009;47(3):804-6. DOI: 10.1128/JCM.01444-08.

56. Scarparo C, Piccoli P, Rigon A, Ruggiero G, Ricordi P, Piersimoni C. Evaluation of the BACTEC MGIT 960 in comparison with BACTEC 460 TB for detection and recovery of mycobacteria from clinical specimens. *Diagn Microbiol Infect Dis* 2002 ;44(2):157-61. DOI: 10.1016/s0732-8893(02)00437-6.

57. Leitritz L, Schubert S, Bucherl B, Masch A, Heesemann J, Roggenkamp A. Evaluation of BACTEC MGIT 960 and BACTEC 460TB systems for recovery of mycobacteria from clinical specimens of a university hospital with low incidence of tuberculosis. *J Clin Microbiol* 2001;39 (10):3764-7. DOI: 10.1128/JCM.39.10.3764-3767.2001.

58. Greenstein RJ, Su L, Haroutunian V, Shahidi A, Brown ST. On the Action of Methotrexate and 6-Mercaptopurine on *M. avium* subspecies *paratuberculosis*. *PLoS ONE* 2007;2(1):e161. (In eng). DOI: 10.1371/journal.pone.0000161.

59. Greenstein RJ, Su L, Juste RA, Brown ST. On the Action of Cyclosporine A, Rapamycin and Tacrolimus on *M. avium* including subspecies *paratuberculosis*. *PLoS ONE* 2008;3(6):e2496. (In eng). DOI: 10.1371/journal.pone.0002496.

60. Greenstein RJ, Su L, Brown ST. The Thioamides Methimazole and Thiourea Inhibit Growth of *M. avium* subspecies *paratuberculosis* in Culture. *PLoS ONE* 2010;5(6):e11099. (Research Support, Non-U.S. Gov't) (In eng). DOI: 10.1371/journal.pone.0011099.

61. Greenstein RJ, Su L, Brown ST. On the effect of thalidomide on *Mycobacterium avium* subspecies *paratuberculosis* in culture. *Int J Infect Dis* 2009;13(5):e254-63. DOI: 10.1016/j.ijid.2008.10.016.

62. Shin SJ, Collins MT. Thiopurine drugs azathioprine and 6-mercaptopurine inhibit *Mycobacterium paratuberculosis* growth in vitro. *Antimicrob Agents Chemother* 2008;52(2):418-26. (Research Support, Non-U.S. Gov't). DOI: 10.1128 /AAC.00678-07.

63. Krishnan MY, Manning EJ, Collins MT. Effects of interactions of antibacterial drugs with each other and with 6-mercaptopurine on in vitro growth of *Mycobacterium avium* subspecies *paratuberculosis*. *J Antimicrob Chemother* 2009;64(5):1018-23. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19759042).

64. Juste RA, Elguezabal N, Garrido JM, et al. On the prevalence of *M. avium* subspecies *paratuberculosis* DNA in the blood of healthy individuals and patients with inflammatory bowel disease. *PLoS One* 2008;3(7):e2537. DOI: 10.1371/journal.pone.0002537.

65. Mellanby E, Green HN. Vitamin A as an Anti-Infective Agent: Its Use in the Treatment of Puerperal Septicaemia. *Br Med J* 1929;1(3569):984-6. (<http://www.ncbi.nlm.nih.gov/pubmed/20774721>).

66. Semba RD. Vitamin A as "anti-infective" therapy, 1920-1940. *J Nutr* 1999;129(4):783-91. (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?c>

Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection

[md=Retrieve&db=PubMed&dopt=Citation&list_uids=10203551](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10203551)).

67. Masten AR. Sunlight in Tuberculosis. *Diseases of the chest* 1935;1(7):8-23.

DOI: <https://doi.org/10.1378/chest.1.7.8>.

68. Saleeby CW. The Advance of Heliotherapy. *Nature* 1922;109(2742):663-663. DOI: 10.1038/109663a0.

69. Bruce D, Ooi JH, Yu S, Cantorna MT. Vitamin D and host resistance to infection? Putting the cart in front of the horse. *Exp Biol Med (Maywood)* 2010;235(8):921-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20660091).

70. Salahuddin N, Ali F, Hasan Z, Rao N, Aqeel M, Mahmood F. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis'. *BMC Infect Dis* 2013;13:22. DOI: 10.1186/1471-2334-13-22.

71. Hewison M. Vitamin D and the intracrinology of innate immunity. *Mol Cell Endocrinol* 2010;321(2):103-11.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20156523).

72. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. *Aliment Pharmacol Ther* 2010;32(3):377-83. (Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't) (In eng). DOI: 10.1111/j.1365-2036.2010.04355.x.

73. Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. *J Biol Chem* 2010;285(4):2227-31.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19948723).

74. Greenstein RJ, Su L, Brown ST. Vitamins A & D inhibit the growth of mycobacteria in radiometric culture. *PLoS ONE* 2012;7(1):e29631. (In eng). DOI: 10.1371/journal.pone.0029631.

75. White JH. Vitamin D deficiency and the pathogenesis of Crohn's disease. *The Journal of steroid biochemistry and molecular biology* 2018 ;175:23-28. DOI: 10.1016/j.jsbmb.2016.12.015.

76. Agtarap A, Chamberlin JW. Monensin, a new biologically active compound. IV. Chemistry. *Antimicrob Agents Chemother (Bethesda)* 1967;7:359-62.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=5596160).

77. Chapman HD, Jeffers TK, Williams RB. Forty years of monensin for the control of coccidiosis in poultry. *Poult Sci* 2010;89(9):1788-801. DOI: 10.3382/ps.2010-00931.

78. Mammi LME, Guadagnini M, Mechor G, et al. The Use of Monensin for Ketosis Prevention in Dairy Cows during the Transition Period: A Systematic Review. *Animals (Basel)* 2021;11(7). DOI: 10.3390/ani11071988.

79. Martineau R, Benchaar C, Petit HV, et al. Effects of lasalocid or monensin supplementation on digestion, ruminal fermentation, blood metabolites, and milk production of lactating dairy cows. *Journal of dairy science* 2007;90(12):5714-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18024764).

80. Greenstein RJ, Su L, Whitlock RH, Brown ST. Monensin causes dose dependent inhibition of *Mycobacterium avium* subspecies paratuberculosis in radiometric culture. *Gut pathogens* 2009;1(1):4. (In eng). DOI: 10.1186/1757-4749-1-4.

81. Greenstein RJ, Cameron DW, Brown ST. "Add-on" is scientifically more accurate than "Placebo control" in multiple Inflammatory Bowel

Human genetic defects and misinterpreted pharmacological data indicate that Crohn disease is consequent to a mycobacterial infection

Disease (IBD) trials. Journal of Crohn's & colitis
2014;8(10):1334-5. DOI: 10.1016/j.crohns.2014.03.015.